Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — Sosei Group — Shareholder Meeting (March 2020)
26 slides from Nxera Pharma's shareholder meeting presentation, Mar 25, 2020
Slide 1: 30th Ordinary General Meeting of Shareholders
NON – CONFIDENTIAL 30 Ordinary General Meeting th of Shareholders Sosei Group Corporation | 第30回定時株主総会 25 March 2020 | 2020年3月25日
Slide 2: Agenda
Agenda 1 Opening Declaration 2 Report on number of voting rights 3 Audit Committee Report 4 FY2019 Results and Business Report 5 Report on Audit Results 6 Resolution 7 Q&A 8 Vote 1
Slide 3: Opening Declaration
1 開会宣言 Opening Declaration 2
Slide 4: Report on the number of voting rights
2 議決権個数のご報告 Report on the number of voting rights 3
Slide 5: Audit Committee Audit Report
3 監査委員会の監査報告 Audit Committee Audit Report 4
Slide 6: FY2019 Consolidated Results Business Report
4 2019年12月期の事業報告 連結業績 FY2019 Consolidated Results Business Report 5
Slide 7: Summary Financial Highlights
Summary Financial Highlights 12 months ended 31 December 2019 1 Significantly improved financials in FY2019 – successful execution of corporate strategy Cash Profit of ¥2,802m ($25.7m) vs. loss of ¥5,704m ($51.7m) in prior corresponding period1, due to 2 strong revenue growth and rigorous focus on c
Slide 8: Consolidated Income Statement
Consolidated Income Statement Significant upfront/milestone payments and prudent cost management delivers profitability JPY million USD million Revenue by Type 12m ended 12m ended 12m ended 12m ended 1 1 31 Dec 2019 31 Dec 2018 31 Dec 2019 31 Dec 2018 3% 10% 15% 11% Revenue 9,726 3,550 89.2 32.2 Cas
Slide 9: COVID-19 situation update
COVID-19 situation update Events and guidance regarding the COVID-19 outbreak continue to change rapidly, and we are 1 monitoring the global situation closely. Our priority remains the health and safety of our employees, visitors and patients in our clinical trials. 2 We have been able to enact our
Slide 10: Unchanged FY2020 Financial Guidance (12m to 31-Dec-20)
Unchanged FY2020 Financial Guidance (12m to 31-Dec-20) Sustainable growth strategy to pursue profitability in 2020 Cash R&D expenses Cash G&A expenses ¥4,200 to 4,700m ¥1,800 to 2,300m Increase number of programs fully New ERP investment to drive Guidance funded by partners efficiencies Group-wi
Slide 11: We achieved a lot in FY2019
We achieved a lot in FY2019 $15m milestone €40m collaboration SSTR5 agonist $2.5m milestone $6m milestones (total) Initiation of Phase 2 Creation of two asset- First subject dosed in Submission of QVM149 Nomination of first two trials of I/O program centric companies with Phase 1 study of MAA to the
Slide 12: Highly productive drug discovery engine generating next wave of high-value, novel candidates
Highly productive drug discovery engine generating next wave of high-value, novel candidates to fuel partnering activity Pre-Discovery / Preclinical Phase 1 Phase 2 Phase 3 Marketed Discovery development Multi-target M1M4 dual ag. A2a ant. A2a ant. combo(s) QVM149 Ultibro® Collaborations Alzheimer’s
Slide 13: Quality, not just speed, is what provides an edge in drug discovery
Quality, not just speed, is what provides an edge in drug discovery Successful drug discovery is best measured by the number of drug candidates delivered Path to Preclinical Candidate– Pharma Industry Standard Path to Preclinical Candidate – Sosei Heptares Drug Discovery Preclinical Drug Discovery P
Slide 14: Strategy leverages proprietary technology and core competencies
Strategy leverages proprietary technology and core competencies Extend technology/platform leadership EXECUTE NEW PARTNERSHIPS AND Generate high quality novel candidates PROGRESS EXISTING that are attractive partnering opportunities PARTNERSHIPS Enhance focus on high value collaboration or long term
Slide 15: Extend technology/platform leadership
Extend technology/platform leadership Technology-led discovery engine has revolutionized GPCR-targeted discovery NEW TECHNIQUE TO ADDING NEW IMAGE BIOMOLECULES Cryo- ? TECHNOLOGIES, TOOLS AND CAPABILITIES IN 2020 EM EXPANDS CAPACITY TO ACCELERATES AND EXPLORE MORE CHESS STAR® AI IMPROVES GPCRs GPCR
Slide 16: Concentrating our efforts in small molecule discovery
Concentrating our efforts in small molecule discovery Small molecules remain of great significance for the industry – and patients Small molecules1 Small molecules Global Pharmaceutical Market Sales (2019)1,2 Other modalities # FDA Novel Drug Approvals Other modalities 59 46 48 63% 64% 69% 63% 2017
Slide 17: Narrowing focus going forward on novel targets across immunology and inflammation
Narrowing focus going forward on novel targets across immunology and inflammation GPCR 20% Therapeutic Targets Areas 44% 50% 30% FUTURE FUTURE 9% 37% 56% Neurology 54% Immunology / Inflammation Other Significant untapped target opportunity. Rich source of exciting targets in Confidently going after
Slide 18: Generate high quality novel candidates attractive to partners
Generate high quality novel candidates attractive to partners Our core competencies are drug discovery and early development DRUG DISCOVERY EARLY DEVELOPMENT LATE STAGE DEVELOPMENT HEALTHY TECHNOLOGY DISCOVERY PRECLINICAL PATIENTS PH 2 PH 3 APPROVAL MARKET VOLUNTEERS BIG BIOTECH / PHARMA P
Slide 19: Targeting high value collaborations & long term ventures
Targeting high value collaborations & long term ventures Unique focus on lower cost, high value add programs Approaches to drug discovery and development Strategic focus on executing new programs to be funded by partners COST Wholly-owned Primary goal is $500m+ deals with High cost / world-lea
Slide 20: Steady state business model generating multiple value inflection points
Steady state business model generating multiple value inflection points New programs every 2 years 4 (to Lead Optimization stage) Programs $ $ $ Programs Programs $ $ $ $ $ $ $ Programs PARTNER PARTNER PARTNER PARTNER Pool of programs 2x PROGRESS Healthy Patient that can be 15+ FURTHER PCC1 Voluntee
Slide 21: Report on Audit Results on the Consolidated Financial Statement
5 連結計算書類の監査結果報告 Report on Audit Results on the Consolidated Financial Statement 20
Slide 22: Matters to be Resolved
6 決議事項 Matters to be Resolved 21
Slide 23: Proposal 1: Election of Six (6) Directors
Proposal 1 Election of Six (6) Directors Chairman of the Board RE-APPOINTED SHINICHI SHINICHI Representative Executive Officer, Chairman, President and CEO TAMURA Chairman of the Nomination Committee TAMURA Member of the Compensation Committee RE-APPOINTED Executive Director TOMOHIRO Chairman of the
Slide 24: Proposal 1: Election of Six (6) Directors
Proposal 1 Election of Six (6) Directors RE-APPOINTED SHINICHI Executive Director DAVID TAMURA Member of the Nomination Committee EXTERNAL ROBLIN Member of the Compensation Committee INDEPENDENT RE-APPOINTED Executive Director NORIAKI Member of the Audit Committee EXTERNAL NAGAI INDEPENDENT NEW APPO
Slide 25: Q&A
7 質疑応答 Q&A 24
Slide 26: Vote
8 採決 Vote 25